Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech outlines a post-GSK plan to operate without going to the capital markets while refocusing on internal development.

You may also be interested in...



Oncology Candidates Stream From Exelixis Discovery Platform

Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.

Oncology Candidates Stream From Exelixis Discovery Platform

Firm will decide whether - and how - to advance three late Phase I compounds in 2009; next big deal likely to focus on PI3/mTOR inhibitors.

Love The One You’re With: BMS Pays Exelixis $240M Upfront In New Cancer Drug Deal

Exelixis re-partners with long-term collaborator BMS the same late-stage XL184 that GSK rejected less than two months earlier.

Related Content

Topics

UsernamePublicRestriction

Register

PS066942

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel